Form 8-K Alector, Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
GSK terminates collaboration with Alector after trial failures
July 8, 2026 4:13 PM EDTAlector Inc. (NASDAQ: ALEC) disclosed that GlaxoSmithKline unit Glaxo Wellcome UK Limited has moved to terminate its collaboration and license agreement with the company, following the failure of two clinical trials.
GSK provided written notice of termination on July 6, 2026. Under the agreement's terms, the... More
